PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-4.70
Negative P/E while AVXL shows 6.53. Joel Greenblatt would examine path to profitability versus competitor.
No Data
No Data available this quarter, please select a different quarter.
-23.32
Both companies show negative equity. Martin Whitman would check for industry-wide restructuring opportunities.
-126.01
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.
-126.09
Both companies show negative operating cash flow. Martin Whitman would check for industry-wide operational issues.
-23.32
Both companies show negative fair values. Martin Whitman would check for industry-wide valuation issues.
-5.32%
Negative earnings while AVXL shows yield of 3.83%. Joel Greenblatt would examine path to profitability.
-0.79%
Both companies show negative FCF. Martin Whitman would check for industry-wide capital intensity issues.